Page 129 - 南京医科大学学报自然科学版
P. 129
第41卷第12期 胡雅慧,郭宏丽,夏 颖,等. 西罗莫司与儿童脉管异常的药物治疗:所知与须知[J].
2021年12月 南京医科大学学报(自然科学版),2021,41(12):1829-1836 ·1835 ·
thelioma:current knowledge and future perspectives[J]. [23] RICCI K W,HAMMILL A M,MOBBERLEY⁃SCHUMAN
Orphanet J Rare Dis,2020,15(1):39 P,et al. Efficacy of systemic sirolimus in the treatment of
[12] LE CRAS T D,MOBBERLEY⁃SCHUMAN P S,BROER⁃ generalized lymphatic anomaly and Gorham⁃Stout disease
ING M,et al. Angiopoietins as serum biomarkers for lym⁃ [J]. Pediatr Blood Cancer,2019,66(5):e27614
phatic anomalies[J]. Angiogenesis,2017,20(1):163- [24] REINGLAS J,RAMPHAL R,BROMWICH M. The suc⁃
173 cessful management of diffuse lymphangiomatosis using
[13] WANG Z,YAO W,SUN H,et al. Sirolimus therapy for ka⁃ sirolimus:a case report[J]. Laryngoscope,2011,121(9):
posiform hemangioendothelioma with long⁃term follow⁃up 1851-1854
[J]. J Dermatol,2019,46(11):956-961 [25] BARCLAY S F,INMAN K W,LUKS V L,et al. A somat⁃
[14] WANG H,GUO X,DUAN Y,et al. Sirolimus as initial ic activating NRAS variant associated with kaposiform
therapy for kaposiform hemangioendothelioma and tufted lymphangiomatosis[J]. Genetics in Medicine,2018,21
angioma[J]. Pediatr Dermatol,2018,35(5):635-638 (7):1517-1524
[15] MARIANI L G,SCHMITT I R,GARCIA C D,et al. Low [26] 王作鹏,孙洪强,李 凯,等.卡波西样淋巴管瘤病的临
dose sirolimus treatment for refractory tufted angioma and 床特点及西罗莫司治疗初探[J]. 中华小儿外科杂志,
congenital kaposiform hemangioendothelioma,both with 2019,40(3):193-197
Kasabach⁃Merritt phenomenon[J]. Pediatr Blood Cancer, [27] JI Y,CHEN S,PENG S,et al. Kaposiform lymphangioma⁃
2019,66(8):e27810 tosis and kaposiform hemangioendothelioma:similarities
[16] ENGEL E R,COURNOYER E,ADAMS D M,et al. A ret⁃ and differences[J]. Orphanet J Rare Dis,2019,14(1):
rospective review of the use of sirolimus for pediatric pa⁃ 165
tients with Epithelioid Hemangioendothelioma(EHE) [28] ZHANG G,CHEN H,ZHEN Z,et al. Sirolimus for treat⁃
[J]. J Pediatr Hematol Oncol,2019,42(8):e826-e829 ment of verrucous venous malformation:a retrospective
[17] MUSALEM H M,ALSHAIKH A A,TULEIMAT L M,et cohort study[J]. J Am Acad Dermatol,2019,80(2):556-
al. Outcome with topical sirolimus for port wine stain mal⁃ 558
formations after unsatisfactory results with pulse dye laser [29] SOBLET J,KANGAS J,NATYNKI M,et al. Blue rubber
treatment alone[J]. Ann Saudi Med,2018,38(5):376- bleb nevus(BRBN)syndrome is caused by somatic TEK
380 (TIE2)mutations[J]. J Invest Dermatol,2017,137(1):
[18] TRIANA JUNCO P E,SANCHEZ⁃CARPINTERO I,LO⁃ 207-216
PEZ⁃GUTIERREZ J C. Preventive treatment with oral si⁃ [30] YOKOYAMA M,OZEKI M,NOZAWA A,et al. Low⁃dose
rolimus and aspirin in a newborn with severe Sturge⁃We⁃ sirolimus for a patient with blue rubber bleb nevus syn⁃
ber syndrome[J]. Pediatr Dermatol,2019,36(4):524- drome[J]. Pediatr Int,2020,62(1):112-113
527 [31] OGU U O,ABUSIN G,ABU⁃ARJA R F,et al. Successful
[19] DODDS M,TOLLEFSON M,CASTELO⁃SOCCIO L,et al. management of blue rubber bleb nevus syndrome
Treatment of superficial vascular anomalies with topical (BRBNS)with sirolimus[J]. Case Rep Pediatr,2018,
sirolimus:a multicenter case series[J]. Pediatr Dermatol, 2018:7654278
2020,37(2):272-277 [32] ZHANG B,LI L,ZHANG N,et al. Efficacy and safety of
[20] LE SAGE S,DAVID M,DUBOIS J,et al. Efficacy and ab⁃ sirolimus in the treatment of blue rubber bleb naevus syn⁃
sorption of topical sirolimus for the treatment of vascular drome in paediatric patients[J]. Clin Exp Dermatol,
anomalies in children:a case series[J]. Pediatr Dermatol, 2020,45(1):79-85
2018,35(4):472-477 [33] 刘建平,刘凤恩,段训洪,等. 儿童先天性动静脉畸形的
[21] LEDUCQ S,CAILLE A,BARBAROT S,et al. Topical si⁃ 治疗[J]. 中华小儿外科杂志,2019,40(1):10-14
rolimus 0.1% for treating cutaneous microcystic lymphat⁃ [34] GABEFF R,BOCCARA O,SOUPRE V,et al. Efficacy
ic malformations in children and adults(TOPICAL):pro⁃ and tolerance of sirolimus(rapamycin)for extracranial ar⁃
tocol for a multicenter phase 2,within ⁃ person,random⁃ teriovenous malformations in children and adults[J]. Ac⁃
ized,double ⁃ blind,vehicle ⁃ controlled clinical trial[J]. ta Derm Venereol,2019,99(12):1105-1109
Trials,2019,20(1):739 [35] VLAHOVIC A M,VLAHOVIC N S,HAXHIJA E Q. Hax⁃
[22] RODRIGUEZ⁃LAGUNA L,AGRA N,IBANEZ K,et al. hija,sirolimus for the treatment of a massive capillary ⁃
Somatic activating mutations in PIK3CA cause general⁃ lymphatico⁃venous malformation:a case report[J]. Pediat⁃
ized lymphatic anomaly[J]. J Exp Med,2019,216(2): rics,2015,136(2):e513-516
407-418 [36] BESSIS D,VERNHET H,BIGORRE M,et al. Life⁃threat⁃